ClinicalTrialStartPulse: Phase 3, page 3 of 4
Records 201 to 350 of the 500 newest listed for this hub. Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
| Record | Phase | Conditions | Enrollment |
|---|---|---|---|
| AbbVie | Phase 3 | Crohn's Disease | 111 |
| AstraZeneca | Phase 3 | Primary Hyperaldosteronism | 212 |
| AstraZeneca | Phase 3 | Biliary Tract Cancer | 760 |
| Pfizer | Phase 3 | Breast Cancer | 1035 |
| AbbVie | Phase 3 | Atopic Dermatitis | 699 |
| AstraZeneca | Phase 3 | Eosinophilic Asthma | 130 |
| SK Life Science, Inc. | Phase 3 | Partial Epilepsy | 154 |
| Vaxcyte, Inc. | Phase 3 | Pneumococcal Disease | 4049 |
| BioNTech SE | Phase 3 | COVID-19; SARS-COV-2 Infection | 5240 |
| Hinova Pharmaceuticals Inc. | Phase 3 | High Risk Biochemical Recurrence (BCR); Deutenzalutamide Soft Capsules | 1044 |
| Onconic Therapeutics Inc. | Phase 3 | H. Pylori Eradication Therapy | 414 |
| Merck Sharp & Dohme LLC | Phase 3 | Pulmonary Disease, Chronic Obstructive | 2136 |
| Pfizer | Phase 3 | Obesity; Overweight | 432 |
| AstraZeneca | Phase 3 | Locally Advanced or Metastatic Breast Cancer | 101 |
| BeOne Medicines | Phase 3 | Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma | 799 |
| AstraZeneca | Phase 3 | Metastatic Non-small Cell Lung Cancer | 768 |
| AstraZeneca | Phase 3 | Breast Cancer | 1174 |
| H. Lundbeck A/S | Phase 3 | Multiple System Atrophy | 401 |
| Merz Therapeutics GmbH | Phase 3 | Chronic Migraine | 808 |
| Merz Therapeutics GmbH | Phase 3 | Episodic Migraine | 997 |
| Teva Branded Pharmaceutical Products R&D LLC | Phase 3 | Asthma | 2772 |
| Takeda | Phase 3 | Psoriatic Arthritis | 601 |
| Amgen | Phase 3 | Obesity; Overweight | 230 |
| Il-Yang Pharm. Co., Ltd. | Phase 3 | Benign Prostatic Hyperplasia | 660 |
| Takeda | Phase 3 | Psoriatic Arthritis | 644 |
| GlaxoSmithKline | Phase 3 | Cardiovascular Disease | 16390 |
| Pfizer | Phase 3 | Obesity and Overweight | 3578 |
| Pfizer | Phase 3 | Obesity; Overweight and/or Obesity; Overweight; Diabetes, Type 2; Type 2 Diabetes | 1078 |
| AbbVie | Phase 3 | Hypothyroidism | 2701 |
| GlaxoSmithKline | Phase 3 | Hypereosinophilic Syndrome | 110 |
| BrightGene Bio-Medical Technology Co., Ltd. | Phase 3 | Type 2 Diabetes (T2DM) | 152 |
| Sanofi | Phase 3 | Dermatitis Atopic | 464 |
| Sanofi | Phase 3 | Dermatitis Atopic | 1856 |
| AstraZeneca | Phase 3 | Esophageal Squamous Cell Carcinoma | 640 |
| Novo Nordisk A/S | Phase 3 | Non-alcoholic Steatohepatitis | 1205 |
| AstraZeneca | Phase 3 | Severe Asthma | 310 |
| AstraZeneca | Phase 3 | Chronic Kidney Disease With High Proteinuria | 1835 |
| Viking Therapeutics, Inc. | Phase 3 | Weight Loss | 560 |
| FrieslandCampina | Phase 3 | Infant ALL | 387 |
| Viking Therapeutics, Inc. | Phase 3 | Weight Loss | 560 |
| AstraZeneca | Phase 3 | NSCLC | 1350 |
| Dermavon Holdings Limited | Phase 3 | NonSegmental Vitiligo | 174 |
| Amgen | Phase 3 | Diabetes Mellitus, Type 2 | 1300 |
| Hoffmann-La Roche | Phase 3 | Cancer | 382 |
| Hoffmann-La Roche | Phase 3 | Diabetic Macular Edema | 672 |
| Hoffmann-La Roche | Phase 3 | NMDAR Autoimmune Encephalitis; LGI1 Autoimmune Encephalitis | 122 |
| Eli Lilly and Company | Phase 3 | Obesity; Overweight | 15374 |
| Pharmazz, Inc. | Phase 3 | Traumatic Brain Injury | 214 |
| Novo Nordisk A/S | Phase 3 | Cardiovascular Risk; Obesity | 8500 |
| GlaxoSmithKline | Phase 3 | Endometrial Carcinoma; Neoplasms, Endometrial | 378 |
| Kailera | Phase 3 | Obesity With Diabetes; Overweight With Diabetes | 1270 |
| Kailera | Phase 3 | Obesity; Overweight | 2530 |
| Eisai Inc. | Phase 3 | Early Alzheimer's Disease | 1906 |
| Kailera | Phase 3 | Obesity | 1270 |
| Teva Branded Pharmaceutical Products R&D LLC | Phase 3 | Asthma | 649 |
| Annexon, Inc. | Phase 3 | Geographic Atrophy | 659 |
| Chiesi Farmaceutici S.p.A. | Phase 3 | Asthma | 700 |
| Genmab | Phase 3 | Ovarian Cancer | 602 |
| Agios Pharmaceuticals, Inc. | Phase 3 | Polycythemia Vera | 245 |
| GL Pharm Tech Corporation | Phase 3 | Erectile Dysfunctions | 228 |
| RayzeBio, Inc. | Phase 3 | GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor | 343 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | Schizophrenia | 538 |
| Epizyme, Inc. | Phase 3 | Relapsed/Refractory Follicular Lymphoma; Follicular Lymphoma; Refractory Follicular Lymphoma | 599 |
| Supergene, LLC | Phase 3 | Acute Limb Ischemia | 170 |
| Jiankuan (Suzhou) Biotechnology Company Limited | Phase 3 | Rheumatoid Arthrits | 590 |
| GlaxoSmithKline | Phase 3 | Respiratory Syncytial Virus Infections | 10212 |
| Novo Nordisk A/S | Phase 3 | Obesity | 609 |
| AstraZeneca | Phase 3 | Systemic Sclerosis; Scleroderma | 314 |
| Genzyme, a Sanofi Company | Phase 3 | Hemophilia | 281 |
| Endo USA Inc., a Keenova Therapeutics Company | Phase 3 | Flexible Hammertoe; Semi-flexible Hammertoe | 470 |
| Ionis Pharmaceuticals, Inc. | Phase 3 | Angelman Syndrome | 156 |
| Idorsia Pharmaceuticals Ltd. | Phase 3 | Insomia Disorder | 344 |
| Pfizer | Phase 3 | Vitiligo | 394 |
| Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 3 | Non-segmental Vitiligo | 480 |
| Ollin Biosciences, Inc. | Phase 3 | Diabetic Macular Edema (DME) | 450 |
| Jemincare | Phase 3 | Renal Edema; Nephrogenic Edema | 240 |
| Ollin Biosciences, Inc. | Phase 3 | Diabetic Macular Edema (DME) | 450 |
| EMD Serono Research & Development Institute, Inc. | Phase 3 | Systemic Lupus Erythematosus (SLE); Cutaneous Lupus Erythematosus (CLE) | 404 |
| Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 3 | Small for Gestational Age | 105 |
| Hoffmann-La Roche | Phase 3 | Alzheimers Disease | 1101 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Diffuse Large B-cell Lymphoma | 282 |
| Hoffmann-La Roche | Phase 3 | Alzheimers Disease | 1060 |
| Janssen Research & Development, LLC | Phase 3 | Ischemic Stroke; Ischemic Attack, Transient | 12523 |
| Janssen Research & Development, LLC | Phase 3 | Metastatic Castrate-sensitive Prostate Cancer | 420 |
| Janssen Research & Development, LLC | Phase 3 | Bladder Cancer | 1135 |
| Janssen Research & Development, LLC | Phase 3 | Urinary Bladder Neoplasms | 518 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Non-small Cell Lung Cancer | 582 |
| Pfizer | Phase 3 | Moderate to Severe Chronic Obstructive Pulmonary Disease | 1360 |
| Pfizer | Phase 3 | Respiratory Syncytial Virus (RSV) | 920 |
| Okyo Pharma Ltd | Phase 3 | Neuropathic Corneal Pain | 111 |
| Merck Sharp & Dohme LLC | Phase 3 | Pulmonary Hypertension | 352 |
| Bristol-Myers Squibb | Phase 3 | Relapsed or Refractory Multiple Myeloma | 606 |
| Biogen | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | 152 |
| BeOne Medicines | Phase 3 | Hepatocellular Carcinoma; Liver Cancer | 492 |
| Hangzhou Sciwind Biosciences Co., Ltd. | Phase 3 | Adolescents With Obesity; Adolescents With Overweight & Weight-related Comorbidities | 192 |
| Brise Pharmaceuticals Co., Ltd. | Phase 3 | Migraine, With or Without Aura | 1000 |
| Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 3 | Neuroendocrine Carcinomas (NEC) | 440 |
| Shanghai Jeyou Pharmaceutical Co., Ltd. | Phase 3 | NSCLC | 416 |
| EMS | Phase 3 | Persistent Allergic Rhinitis | 316 |
| Sinovac Life Sciences Co., Ltd. | Phase 3 | Pneumococcal Infectious Diseases | 1125 |
| Amgen | Phase 3 | Relapsing-remitting Multiple Sclerosis (RRMS) | 152 |
| Takeda | Phase 3 | Dengue Fever | 800 |
| EMD Serono Research & Development Institute, Inc. | Phase 3 | Solid Tumors | 205 |
| BioRay Pharmaceutical Co., Ltd. | Phase 3 | Primary Membranous Nephropathy | 150 |
| Genascence Corporation | Phase 3 | Knee Arthritis Osteoarthritis; Knee Arthritis, Osteoarthritis; Knee Arthritis; Knee Arthritis Disease; Osteo Arthritis of the Knee; Osteoarthritic Knee Pain | 240 |
| Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 3 | Lung Squamous Cell Carcinoma | 600 |
| Merck Sharp & Dohme LLC | Phase 3 | Bladder Cancer | 400 |
| RemeGen Co., Ltd. | Phase 3 | Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations | 540 |
| Medprin Regenerative Medical Technologies Co., Ltd. | Phase 3 | Surgical Bleeding | 324 |
| Hoffmann-La Roche | Phase 3 | Early Breast Cancer; Estrogen Receptor-Positive Breast Cancer; HER2-Negative Breast Cancer | 1500 |
| Merck Sharp & Dohme LLC | Phase 3 | Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis | 4390 |
| Sol-Gel Technologies, Ltd. | Phase 3 | Gorlin Syndrome | 113 |
| Ono Pharmaceutical Co., Ltd. | Phase 3 | Multiple System Atrophy, Parkinson Variant | 486 |
| Vivace Therapeutics, Inc | Phase 3 | Pleural Mesothelioma; Mesothelioma | 350 |
| Bristol-Myers Squibb | Phase 3 | Multiple Myeloma | 1230 |
| Stealth BioTherapeutics Inc. | Phase 3 | Age Related Macular Degeneration (ARMD) | 313 |
| Amgen | Phase 3 | Obesity | 3853 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Carcinoma, Non-Small-Cell Lung | 448 |
| Hansoh BioMedical R&D Company | Phase 3 | Platinum-sensitive Recurrent Ovarian Cancer | 460 |
| AbbVie | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | 660 |
| Ono Pharmaceutical Co., Ltd. | Phase 3 | Gastric Cancer; Esophagogastric Junction Cancer; Esophageal Adenocarcinoma | 600 |
| Assiut University | Phase 3 | Bladder Cancer; TURBT; Radiotherapy | 71 |
| M.D. Anderson Cancer Center | Phase 3 | Multiple Actinic Keratoses | 18 |
| Zhejiang Cuize Pharmaceutical Technology Co., Ltd. | Phase 3 | Hemorrhoids Second Degree; Hemorrhoids Third Degree; Analgesia | 243 |
| Assiut University | Phase 3 | Pain Management | 90 |
| Nanjing First Hospital, Nanjing Medical University | Phase 3 | Helicobacter Infection | 612 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Phase 3 | Acute Ischemic Stroke; Large Vessel Occlusion | 314 |
| Ain Shams University | Phase 3 | Comparative Effectiveness | 100 |
| Tanta University | Phase 3 | NAFLD (Nonalcoholic Fatty Liver Disease) | 60 |
| Tanta University | Phase 3 | NAFLD (Nonalcoholic Fatty Liver Disease) | 60 |
| Fundació d'investigació Sanitària de les Illes Balears | Phase 3 | Traumatic Brain Injury (TBI) Patients | 536 |
| The George Institute | Phase 3 | Septic Shock | 2200 |
| Dayanand Medical College and Hospital | Phase 3 | Alcoholic Hepatitis | 174 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 3 | Lipodystrophy; Diabetes; Hyperlipidemia | 24 |
| Walter Reed National Military Medical Center | Phase 3 | Discogenic Low Back Pain | 60 |
| Tanta University | Phase 3 | Lactium; Premedication; Emergence Agitation; Adenotonsillectomy; Dose Finding Study | 40 |
| Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | Myelodysplastic Syndromes | 75 |
| Shanghai University of Traditional Chinese Medicine | Phase 3 | Primary Osteoporosis | 300 |
| University Health Network, Toronto | Phase 3 | Hepatocellular Carcinoma (HCC) | 60 |
| Cairo University | Phase 3 | Psoriasis; Psoriasis Genital | 40 |
| The Cleveland Clinic | Phase 3 | Atrial Fibrillation; Postoperative Atrial Fibrillation | 60 |
| Ruijin Hospital | Phase 3 | Esophageal Cancer | 160 |
| Memorial Sloan Kettering Cancer Center | Phase 3 | Malignant Melanoma of Skin; Other and Unspecified Malignant Neoplasm of Skin; Melanoma in Situ; Carcinoma in Situ of Skin; Hemangioma; Melanocytic Nevi | 14000 |
| Ionis Pharmaceuticals, Inc. | Phase 3 | Angelman Syndrome | 30 |
| Minghui Pharmaceutical (Hangzhou) Ltd | Phase 3 | Thyroid Eye Disease, TED | 84 |
| Novo Nordisk A/S | Phase 3 | Heart Failure | 4874 |
| AFT Pharmaceuticals, Ltd. | Phase 3 | Acute Pain | 60 |
| Immunovant Sciences GmbH | Phase 3 | Generalized Myasthenia Gravis | 233 |
| Neumora Therapeutics, Inc. | Phase 3 | Major Depressive Disorder | 904 |
| Hellenic Institute for the Study of Sepsis | Phase 3 | Type 1 Diabetes Mellitus |
All ClinicalTrialStartPulse record reports